Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Raises Target Price to $7

Moomoo NewsFeb 20 08:31 ET · Ratings

Analysts Are Bullish on Top Healthcare Stocks: Chemomab Therapeutics (CMMB), Blueprint Medicines (BPMC)

TipRanksFeb 20 08:10 ET · Ratings

Oppenheimer Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $11

Moomoo NewsFeb 19 08:31 ET · Ratings

Market-Moving News for February 19th

BenzingaFeb 19 07:23 ET

Express News | Chemomab Therapeutics Shares Are Trading Higher After the Company Announced the Completion of Its End-of-phase 2 FDA Meeting and Alignment on a Single Phase 3 Registration Study for Nebokitug

BenzingaFeb 19 07:17 ET

Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns With FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis

GlobeNewswireFeb 19 07:00 ET

Chemomab Therapeutics Aligns Leadership Incentives With Shareholders

TipRanksNov 18, 2024 16:50 ET

Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $4

Moomoo NewsNov 15, 2024 15:31 ET · Ratings

Oppenheimer Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Cuts Target Price to $11

Moomoo NewsNov 15, 2024 14:31 ET · Ratings

Chemomab Therapeutics Analyst Ratings

BenzingaNov 15, 2024 10:53 ET · Ratings

Express News | Chemomab Therapeutics Ltd. : Oppenheimer Cuts Target Price to $11 From $13

ReutersNov 15, 2024 08:27 ET

Chemomab Therapeutics Sees Cash Runway Through Beginning of 2026

TipRanksNov 14, 2024 07:11 ET

Express News | Chemomab Therapeutics Q3 2024 GAAP EPS $(0.20) Misses $(0.01) Estimate

BenzingaNov 14, 2024 07:07 ET

Chemomab Therapeutics 3Q EPS 1c >CMMB

Dow JonesNov 14, 2024 07:02 ET

Earnings Scheduled For November 14, 2024

BenzingaNov 14, 2024 03:32 ET

Earnings Preview: CMMB to Report Financial Results Pre-market on November 14

Moomoo NewsNov 8, 2024 20:00 ET

Express News | Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update

ReutersOct 30, 2024 07:00 ET

Roth MKM Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $9

Moomoo NewsOct 18, 2024 09:34 ET · Ratings

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

BenzingaOct 15, 2024 08:08 ET

Express News | Chemomab Therapeutics Announces Late-Breaking Oral Presentation of Cm-101 Phase 2 Results in Primary Sclerosing Cholangitis at Aasld the Liver Meeting® 2024

ReutersOct 15, 2024 07:00 ET